The studies are part of Guard Therapeutics’ strategy to develop ROSgard as a protective treatment against acute kidney injury in several patient segments, initially in patients undergoing open heart surgery. The experimental results, which show that ROSgard protects against serious types of injury to both the liver and kidneys, thus strengthen the company’s future opportunities to expand the clinical use of ROSgard to broader patient groups with great medical need where there are currently no effective treatments.
In the studies, which were carried out in collaboration with researchers at the
“The positive study results indicate that the future use of ROSgard can potentially be expanded to additional areas where there is a great need for better treatments, such as sepsis. The results also strengthen the hypothesis that our investigational drug’s protective mechanisms are not specific to the kidneys but can be generalised to other organs and tissues, which can be beneficial in a variety of acute medical conditions including heart surgery,” Guard Therapeutics’ CEO,
Among other properties, the investigational drug ROSgard has the ability to counteract severe oxidative stress, which is a common denominator for many types of acute kidney injury. In the initial clinical development phase
© Modular Finance, source